Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,002,186 papers from all fields of science
Search
Sign In
Create Free Account
CardioSeal Septal Occluder
Known as:
CardioSeal Septal Occluders
, Septal Occluders, CardioSeal
, Septal Occluder, CardioSeal
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Septal Occluder Device
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale.
M. Hornung
,
S. Bertog
,
+6 authors
H. Sievert
European Heart Journal
2013
Corpus ID: 205026251
AIMS Percutaneous patent foramen ovale (PFO) closure for secondary stroke prevention is discussed controversially. Long-term data…
Expand
Highly Cited
2008
Highly Cited
2008
Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder).
M. Taaffe
,
E. Fischer
,
+11 authors
H. Sievert
American Journal of Cardiology
2008
Corpus ID: 38496718
2008
2008
Late presentation of CardioSEAL PFO closure device fracture and thrombus formation three years after device implantation.
Vidya Narayan
,
P. Puri
,
A. Mehra
The Journal of invasive cardiology
2008
Corpus ID: 37031978
Transcatheter closure of patent foramen ovale (PFO) is a promising alternative to surgical closure or anticoagulation therapy in…
Expand
Highly Cited
2004
Highly Cited
2004
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems.
M. Braun
,
V. Gliech
,
+6 authors
R. Strasser
European Heart Journal
2004
Corpus ID: 6275406
2004
2004
CardioSEAL/STARflex versus Amplatzer devices for percutaneous closure of small to moderate (up to 18 mm) atrial septal defects
G. Butera
,
M. Carminati
,
+5 authors
A. Frigiola
2004
Corpus ID: 73040135
2004
2004
CardioSEAL/STARflex versus Amplatzer devices for percutaneous closure of small to moderate (up to 18 mm) atrial septal defects.
G. Butera
,
M. Carminati
,
+5 authors
A. Frigiola
American Heart Journal
2004
Corpus ID: 30474773
2002
2002
[Interventional occlusion of foramen ovale and atrial septal defects after paradoxical embolism incidents].
A. Beitzke
,
H. Schuchlenz
,
M. Beitzke
,
A. Gamillscheg
,
H. Stein
,
P. Zartner
Zeitschrift für Kardiologie
2002
Corpus ID: 25344735
Two hundred and fifty-one patients with a persistent foramen ovale (PFO), mean age 43.3 +/- 12.4 years, underwent catheter…
Expand
2002
2002
Interventioneller Verschluss von Foramen ovale und Vorhofseptumdefekten nach paradox embolischen Ereignissen
A. Beitzke
,
H. Schuchlenz
,
M. Beitzke
,
A. Gamillscheg
,
H. Stein
,
P. Zartner
Zeitschrift für Kardiologie
2002
Corpus ID: 44887765
Two hundred and fifty-one patients with a persistent foramen ovale (PFO), mean age 43.3±12.4 years, underwent catheter closure…
Expand
Highly Cited
2001
Highly Cited
2001
Patent foramen ovale closure in patients with transient ischemia attack/stroke.
H. Sievert
,
K. Horvath
,
+8 authors
H. Lissmann-Jensen
Journal of interventional cardiology
2001
Corpus ID: 33568764
Paradoxical embolism through a patent foramen ovale (PFO) has been recognized as a potential cause of transient ischemia attack…
Expand
Highly Cited
2001
Highly Cited
2001
Catheter closure of atrial septal defects and patent foramen ovale in patients with an atrial septal aneurysm using different devices.
U. Krumsdorf
,
P. Keppeler
,
K. Horvath
,
E. Zadan
,
R. Schrader
,
H. Sievert
Journal of interventional cardiology
2001
Corpus ID: 38967532
BACKGROUND Atrial septal aneurysm is frequently associated with patent foramen ovale (PFO) and atrial septal defects (ASD…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE